Maite Begoña Gorostegui Obanos
Investigador
Research group
SJD Barcelona Children's Hospital Last Publications
- Santa-María López V, Felip-Badia A, Marina Caballero Bellón, Sanchez-Sierra N, Castañeda-Heredia A, Garraus-Oneca M, Gorostegui M, Simão-Rafael M, Muñoz JP, Pérez-Somarriba M, Mañe S, Planells MC, Pérez-Jaume S and Mora J Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse PEDIATRIC BLOOD & CANCER . : .
- Aurensanz E, Garcia P, Gorostegui M, Rivera C, Escobar MC, Randanne P, Morales-La Madrid A and Sanchez deToledo J Uncovering subclinical cardiotoxicity across chemotherapy phases in pediatric oncology Frontiers in Oncology . 15: 1623081-1623081.
- Sampor C, Alonso R, Durañona M, Gorostegui M, Antillón-Klussmann F, Lopes LF, Cappellano AM, Gonzalez-Ramella O, Lobos P, Palma J, Grynszpancholc E, Vasquez L, Morales-La Madrid A, Moreira DC, Cruz-Martínez O and Chantada G The TeLeo Program: Tele-education in pediatric oncology as a tool to support training programs in Latin America PEDIATRIC BLOOD & CANCER . 71(12): .
Projects
- Project name:
- UNCAN-Connect: Decentralized Collaborative Network for Advancing Cancer Research and Innovation
- Leader
- Joan Sánchez de Toledo
- Funding entities:
- European Commission
- Code
- 101215206
- Starting - finishing date:
- 2025 - 2030
- Project name:
- Multi-ómica y cribado masivo de fármacos para el tratamiento dirigido del Neuroblastoma resistente al tratamiento
- Leader
- Cinzia Emilia Lavarino , Marta García López
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI23/00120
- Starting - finishing date:
- 2024 - 2026
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
